Daphnetin
CAS 486-35-1
Daphnetin (CAS 486-35-1) is a pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 17788.153623188406 nM | 66 | - |
| - | IC50 | 25216.867619047618 nM | 21 | - |
| - | MIC | 29.142857142857142 ug.mL-1 | 7 | - |
| - | AC50 | 14219.09 nM | 2 | - |
| - | IC50 | 4.34 ug.mL-1 | 1 | - |
| - | Ki | 1750 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| DAPHNETIN | 2686292 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Daphnetin used for in pharmaceutical contexts?
Daphnetin (CAS 486-35-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Daphnetin?
No adverse-event association or SIDER side-effect rows are rendered for Daphnetin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Daphnetin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Daphnetin with EU status "prohibited".
What clinical phase is Daphnetin in?
No phase 1-4 clinical development badge is rendered for Daphnetin because the matched compound identifier rows do not contain a max-phase value.